-
2 months ago | 
outsourcedpharma.com | Louis Garguilo |Allan Marinelli |Abhijit Menon |Brian Graves
Take a tour of Nanoform's best-in-class nanodevelopment capabilities, setting new standards in innovation. Their highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs. With 14 development lines for small molecules and 5 for large molecules, Nanoform offers unmatched scalability and precision. Leveraging cutting-edge technology, they produce nanoformed materials as small as 10 nanometers. Learn more.
-
Jan 24, 2025 | 
pharmaceuticalonline.com | Allan Marinelli |Abhijit Menon
By Allan Marinelli and Abhijit Menon
When work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver or by creating unnecessary work that reduces efficiency – this can result in pharmaceutical, medical device, cell & gene therapy, and vaccine companies losing profits, efficiencies, and effectiveness.
-
Dec 7, 2024 | 
meddeviceonline.com | Mark Witcher |Allan Marinelli |Abhijit Menon |Brett Mason
This article puts a new lens on the risk model in Annex C of ISO 14971 using relational risk analysis to describe a better approach for understanding and managing medical device risks. In part 2 of the authors' series on computer systems validation pitfalls, they cover misinterpretations and unnecessary "nice to haves" that waste execution efficiencies.
-
Nov 26, 2024 | 
laboratorynetwork.com | Allan Marinelli |Abhijit Menon
In part 2 of the authors' series on computer systems validation pitfalls, they cover misinterpretations and unnecessary "nice to haves" that waste execution efficiencies.
-
Nov 25, 2024 | 
pharmaceuticalonline.com | Allan Marinelli |Abhijit Menon
By Allan Marinelli and Abhijit Menon
When work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver or by creating unnecessary work that reduces efficiency – this can result in pharmaceutical, medical device, cell & gene therapy, and vaccine companies losing profits, efficiencies, and effectiveness.
-
Nov 12, 2024 | 
laboratorynetwork.com | Allan Marinelli |Abhijit Menon
By Allan Marinelli and Abhijit MenonWhen computer systems validation work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver — this can result in drug and device companies losing profits and efficiencies.
-
Oct 29, 2024 | 
pharmaceuticalonline.com | Allan Marinelli |Abhijit Menon
By Allan Marinelli and Abhijit Menon
When work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver or by creating unnecessary work that reduces efficiency — this can result in pharmaceutical, medical device, cell & gene therapy, and vaccine companies losing profits, efficiencies, and effectiveness.
-
Oct 29, 2024 | 
bioprocessonline.com | Allan Marinelli |Abhijit Menon
By Allan Marinelli and Abhijit Menon
When work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver or by creating unnecessary work that reduces efficiency — this can result in pharmaceutical, medical device, cell & gene therapy, and vaccine companies losing profits, efficiencies, and effectiveness.
-
Oct 9, 2024 | 
pharmaceuticalonline.com | Allan Marinelli |Abhijit Menon
Guest Column
| October 9, 2024
By Allan Marinelli and Abhijit Menon
When work is not performed according to protocol instructions — by cutting corners on quality outputs with the focus on profit as the main driver or by creating unnecessary work that reduces efficiency — this can result in pharmaceutical, medical device, cell & gene therapy, and vaccine companies losing profits, efficiencies, and effectiveness.
-
Aug 7, 2023 | 
lifescienceleader.com | Allan Marinelli |Laura Morgan Roberts
Sign up today for your FREE subscription to Life Science Leader Magazine! sign me up Guest Column | August 7, 2023 By Allan Marinelli & Laura Roberts It is important for the pharmaceutical, biopharmaceutical, and medical device industries to obtain the most qualified candidates during these fast technological times for either the short- or long-term (i.e., specialized consultants) or direct hire full-time employees. In this article, we’re going to focus on hiring the right qualified...
